Blocking CB1 Receptors Makes Pesticide Poisoning Worse in Rats ↗
Rat study found blocking CB1 receptors worsened pesticide poisoning, suggesting the endocannabinoid system naturally protects against organophosphorus toxicity.
Browse more cannabis research, findings, methods, and limitations.
Rat study found blocking CB1 receptors worsened pesticide poisoning, suggesting the endocannabinoid system naturally protects against organophosphorus toxicity.
Clinical review of cannabinoid hyperemesis syndrome, a paradoxical condition where long-term marijuana use causes severe recurrent vomiting that resolves only with cannabis cessation.
Landmark review by endocannabinoid research pioneers mapped the system's roles across reproduction, bone, skin, immunity, and gut function, establishing it as one of the body's most widespread signaling networks.
Auckland detox services saw 47 synthetic cannabinoid withdrawal presentations in one year, with 20 requiring inpatient care. It became the third largest detox admission category.
Scottish study of 500 smokers found adding cannabis to tobacco was associated with worse respiratory symptoms and a small increase in COPD rates beyond tobacco alone.
Case report of a 32-year-old man with 19 years of daily cannabis use who developed cannabinoid hyperemesis syndrome, successfully treated with lorazepam and hot showers.
School-based program targeting personality risk factors delayed cannabis use in high-risk teens, with sensation-seekers 75% less likely to start using over 24 months.
Review found cannabinoid receptors throughout the GI tract regulate nausea and vomiting, but clinical evidence for visceral pain relief in conditions like IBS was lacking.
Vaporized THC at higher doses helped rats extinguish opiate withdrawal memories, while injected THC at a moderate dose prolonged them fourfold, highlighting route-dependent effects.
Rat study found estrogen and progesterone promoted THC dependence and withdrawal symptoms, while testosterone appeared protective, potentially explaining sex differences in cannabis withdrawal.
MRI study found young adult cannabis users had thinner cortex in the fusiform gyrus and smaller thalamic volumes linked to greater impulsivity compared to matched non-users.
Study of nine Cannabis sativa varieties found cold-hardy types activated specific genes and epigenetic changes during cold acclimation that less hardy varieties could not.
Cannabis use remained stable during the first year of methadone treatment, linked to opioid use and health problems rather than methadone itself, suggesting self-medication.
Review found CBD and other non-psychoactive cannabinoids inhibited multiple cancer types in animal models through diverse mechanisms and enhanced standard chemotherapy drug activity.
Study of 94 methadone patients found cannabis users had significantly lower methadone blood levels, potentially affecting treatment effectiveness. No heroin use was reported above specific concentration thresholds.
New CB1 receptor blocker ENP11 reduced food intake and blocked endocannabinoid-driven overeating in rats without affecting pain or motor function.
Review found marijuana crosses the placenta and appears in breast milk, with evidence linking prenatal exposure to growth restriction and neurological development effects, though data quality is limited.
National survey data showed drug-free workplace policies and EAPs were each associated with 15% lower odds of marijuana use and prescription drug misuse in young workers.
Randomized trial of 1,874 sixth-graders showed a universal prevention program reduced cannabis use across all risk levels, with the largest absolute effect for high-risk children.
National survey found 28% of African American substance users used both marijuana and tobacco, with co-users showing higher marijuana dependence and earlier age of initiation.
Study of 205 psychosis patients found those who previously used prescription stimulants developed psychosis four years earlier on average, independent of cannabis use or family history.
Australian review found limited evidence for medicinal cannabis in MS spasticity, cancer nausea, and pain, emphasizing the need for regulatory frameworks as access expands.
Case report of cannabinoid hyperemesis syndrome with atypical features including bradycardia and cold-water relief instead of the classic hot-water relief pattern.
Review found alcohol promotes inflammation while cannabinoids suppress it, suggesting cannabinoid-based therapies could potentially counteract alcohol-induced immune damage.
Mouse study found MAGL inhibition (raising 2-AG) worsened hypothermia from cold and infection via CB1 receptors, while FAAH inhibition (raising anandamide) had no temperature effect.
Mice lacking the FAAH enzyme were completely protected from migraine-like pain, and FAAH-inhibiting drugs reproduced this protection through CB1 receptors.
Economic analysis found repressive cannabis policies are costly without reducing use, while regulated legalization could cut enforcement costs and generate revenue without a consumption spike.
Mouse study found synthetic cannabinoid JWH-018 impaired sensory function at very low doses and caused convulsions at high doses, effects not seen with equivalent THC doses.
Review found cannabinoids may counter chemotherapy-induced nausea, bone loss, kidney damage, heart damage, pain, and insomnia, based on preclinical and early clinical evidence.
Survey of 2,002 college students found 17% allowed marijuana smoking in their homes versus 14.5% for cigarettes, with different social factors predicting each.
CBG was the most effective non-psychoactive cannabinoid at reducing bladder contractions in mice and human tissue, working through a non-CB1/CB2 mechanism.
Genetic analysis of 2,596 people found common gene variants explain 25-36% of drug dependence vulnerability, with genetic effects almost entirely shared across substances.
Review found no approved cannabis addiction medications but identified promising targets including FAAH inhibitors and allosteric CB1 modulators in animal models of reward, withdrawal, and relapse.
56% of South African teens with first-episode psychosis reported cannabis use (96% male), with an average 7-month delay before treatment began.
Review mapped non-psychoactive cannabinoid strategies for cancer treatment, including CB2-selective agents and enzyme inhibitors from both cannabis and non-cannabis plants.
Hepatitis C patients had elevated endocannabinoids that suppressed antiviral immunity and promoted liver scarring, potentially explaining why cannabis worsens liver disease progression.
Canadian national survey found 3.9% past-year depression prevalence, with about 5% of depressed individuals also having cannabis use disorders. 63% sought treatment but 38% perceived stigma.
Pharmacological review identified 13 probable endocannabinoids in mammalian tissue, including agonists, antagonists, and allosteric modulators, revealing the system's built-in regulatory complexity.
Review highlighted CB1's potential in brain protection and addiction, CB2's potential in ALS, HIV neuroinflammation, and osteoporosis, emphasizing the need for receptor-selective cannabinoid drugs.
Survey of 6,530 cannabis growers across 11 countries found most grew for personal use, came from normal backgrounds, and had minimal involvement in other criminal activity.
Researchers designed CB2-selective inverse agonist compounds with no CB1 activity, including novel noncompetitive antagonists, expanding the toolkit for non-psychoactive cannabinoid therapeutics.
Among 75 children given cannabis extracts for epilepsy, parents reported 33% had seizures cut in half, with dramatic differences by syndrome type. But 44% had side effects including worsened seizures.
Review found cannabinoids relieve MS spasticity and showed neuroprotective potential in animal models of both MS and ALS, suggesting possible disease-modifying effects.
Synthetic CBD slowed MS-related disability in mice possibly via sodium channels, while THC slowed progression without suppressing relapses. A clinical trial subgroup also showed THC benefit.
Review found tobacco and cannabis each promote dependence on the other through shared brain chemistry, common smoking route, and bidirectional gateway effects.
Scientists discovered seven new cannabinoids in high-potency cannabis, with one showing higher CB1 binding and more potent THC-like effects than delta-8-THC.
Researchers designed pyrrole-based compounds with high CB2 selectivity and antagonist/inverse agonist activity, advancing the development of non-psychoactive anti-inflammatory cannabinoid drugs.
Qualitative study found young adults with psychosis who quit cannabis naturally relied on recognizing broad harms, social support, diverse coping strategies, and peer pressure resistance.
First-grade attention problems predicted marijuana use by seventh grade in African American youth, while externalizing behavior predicted drug exposure opportunities during the high school transition.
Study of 144 adolescent offenders in Spain found 78.5% used drugs, with psychotic teens preferring cannabis and ADHD teens gravitating toward cannabis plus cocaine.